Literature DB >> 33104881

Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.

David C A Molitor1, Peter Boor2, Andreas Buness3,4, Rebekka K Schneider5,6, Lino L Teichmann7, Ruth-Miriam Körber7, Gabor L Horvath8, Steffen Koschmieder9, Ines Gütgemann10.   

Abstract

Bone marrow (BM) fibrosis in myeloproliferative neoplasms (MPNs) is associated with a poor prognosis. The development of myelofibrosis and differentiation of mesenchymal stromal cells to profibrotic myofibroblasts depends on macrophages. Here, we compared macrophage frequencies in BM biopsies of MPN patients and controls (patients with non-neoplastic processes), including primary myelofibrosis (PMF, n = 18), essential thrombocythemia (ET, n = 14), polycythemia vera (PV, n = 12), and Philadelphia chromosome-positive chronic myeloid leukemia (CML, n = 9). In PMF, CD68-positive macrophages were greatly increased compared to CML (p = 0.017) and control BM (p < 0.001). Similar findings were observed by CD163 staining (PMF vs. CML: p = 0.017; PMF vs. control: p < 0.001). Moreover, CD68-positive macrophages were increased in PV compared with ET (p = 0.009) and reactive cases (p < 0.001). PMF had higher frequencies of macrophages than PV (CD68: p < 0.001; CD163: p < 0.001) and ET (CD68: p < 0.001; CD163: p < 0.001). CD163 and CD68 were often co-expressed in macrophages with stellate morphology in Philadelphia chromosome-negative MPN, resulting in a sponge-like reticular network that may be a key regulator of unbalanced hematopoiesis in the BM space and may explain differences in cellularity and clinical course.

Entities:  

Keywords:  Bone marrow fibrosis; Immunohistochemistry; Macrophages; Myeloproliferative neoplasm

Year:  2020        PMID: 33104881     DOI: 10.1007/s00277-020-04304-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  25 in total

1.  Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.

Authors:  M A Elliott; S Verstovsek; D Dingli; S M Schwager; R A Mesa; C Y Li; A Tefferi
Journal:  Leuk Res       Date:  2007-03-29       Impact factor: 3.156

2.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

Review 3.  Inflammation and myeloproliferative neoplasms.

Authors:  Federico Lussana; Alessandro Rambaldi
Journal:  J Autoimmun       Date:  2017-06-30       Impact factor: 7.094

4.  Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis.

Authors:  Kanako Wakahashi; Kentaro Minagawa; Yuko Kawano; Hiroki Kawano; Tomohide Suzuki; Shinichi Ishii; Akiko Sada; Noboru Asada; Mari Sato; Shigeaki Kato; Kotaro Shide; Kazuya Shimoda; Toshimitsu Matsui; Yoshio Katayama
Journal:  Blood       Date:  2019-02-04       Impact factor: 22.113

5.  Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis.

Authors:  Marco Romano; Daria Sollazzo; Sara Trabanelli; Martina Barone; Nicola Polverelli; Margherita Perricone; Dorian Forte; Simona Luatti; Michele Cavo; Nicola Vianelli; Camilla Jandus; Francesca Palandri; Lucia Catani
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

Review 6.  The regulation of JAKs in cytokine signaling and its breakdown in disease.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Juuli Raivola; Olli Silvennoinen
Journal:  Cytokine       Date:  2018-05-21       Impact factor: 3.861

7.  Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.

Authors:  Orianne Wagner-Ballon; Hédia Chagraoui; Eric Prina; Micheline Tulliez; Geneviève Milon; Hana Raslova; Jean-Luc Villeval; William Vainchenker; Stéphane Giraudier
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

8.  Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.

Authors:  Rebekka K Schneider; Ann Mullally; Aurelien Dugourd; Fabian Peisker; Remco Hoogenboezem; Paulina M H Van Strien; Eric M Bindels; Dirk Heckl; Guntram Büsche; David Fleck; Gerhard Müller-Newen; Janewit Wongboonsin; Monica Ventura Ferreira; Victor G Puelles; Julio Saez-Rodriguez; Benjamin L Ebert; Benjamin D Humphreys; Rafael Kramann
Journal:  Cell Stem Cell       Date:  2017-04-27       Impact factor: 24.633

9.  Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.

Authors:  Srdan Verstovsek; Taghi Manshouri; Darrell Pilling; Carlos E Bueso-Ramos; Kate J Newberry; Sanja Prijic; Liza Knez; Ksenija Bozinovic; David M Harris; Erika L Spaeth; Sean M Post; Asha S Multani; Raajit K Rampal; Jihae Ahn; Ross L Levine; Chad J Creighton; Hagop M Kantarjian; Zeev Estrov
Journal:  J Exp Med       Date:  2016-08-01       Impact factor: 14.307

Review 10.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Authors:  Hans Carl Hasselbalch; Mads Emil Bjørn
Journal:  Mediators Inflamm       Date:  2015-10-28       Impact factor: 4.711

View more
  3 in total

Review 1.  Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.

Authors:  Lilian Varricchio; Ronald Hoffman
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

Review 2.  Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies.

Authors:  Virginia Camacho; Valeriya Kuznetsova; Robert S Welner
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

Review 3.  JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.

Authors:  Dania G Torres; Jhemerson Paes; Allyson G da Costa; Adriana Malheiro; George V Silva; Lucivana P de Souza Mourão; Andréa M Tarragô
Journal:  Biomolecules       Date:  2022-02-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.